Pfizer.
American multinational pharmaceutical and biotechnology corporation
- Reports this week
- 22
- Active events
- 17
- Connections
- 742
What's happening
Active this week
-
Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Some support2 reports
-
MarketBeat's screener has identified a list of dividend stocks.Well supported15 reports1 development inside
-
Pfizer and other companies are facing administration policy guidance regarding higher drug prices abroad in exchange for revenue sharing with HHS.Some support2 reports
-
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Well supported10 reports7 developments inside
-
Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.Well supported131 reports40 developments inside
-
FDA granted approval for Pfizer's updated vaccine on September 2, 2025.Well supported4 reports
-
GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.Some support1 report
-
IMA Group operates a production site and manufacturing plant in Tonawanda, New York, providing specialized equipment to major customers like Pfizer and Moderna.Some support1 report
-
Former Pfizer HQ in Manhattan is discussed alongside Los Angeles as examples of major urban centers facing development challenges and structural issues.Some support1 report
-
Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.Some support2 reports1 development inside
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support1 report
-
Pfizer, AT&T, and Verizon are companies that trade on the New York Stock Exchange.Some support3 reports
-
Kraft Heinz, Pfizer, and United Parcel Service are all facing financial challenges.Some support1 report
-
Pfizer and Eli Lilly are being discussed as potential dividend investment targets.Some support2 reports
-
Pfizer and Seagen are growing their older-adult vaccine market share by expanding the Prevnar 20 vaccination program and rebuilding their commercial model around acquired products.Some support1 report
-
Pfizer has refused to cooperate with local investigators regarding an incident in Karnataka.Some support2 reports
Earlier this month
-
Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.Some support2 reports
-
MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.Some support1 report
-
The FDA suspended Pfizer's C&F Depot license.Some support2 reports
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
-
The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.Some support2 reports
-
Trump promised drug discounts for low-income Americans and discussed Pfizer deals at a Dallas convention.Some support4 reports
-
Pfizer CEO Ugur Sahin sold shares of the firm's stock.Some support3 reports
-
Vaxcyte is targeting the market dominated by Pfizer, and a key individual involved in the story previously worked at Pfizer.Some support1 report
-
The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.Well supported6 reports1 development inside
-
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Some support3 reports4 developments inside
-
Pfizer and Boeing were tokenized for use in a crypto launchpad.Some support1 report
-
Pfizer conducted initial clinical trials under government review.Some support1 report1 development inside
-
DHS is piloting the 340B program, which affects products manufactured by Pfizer.Some support2 reports
-
Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.Some support2 reports
-
Rand Paul released Fauci's diary ahead of a hearing, while Israel provided Pfizer vaccine data to shape US booster policy.Some support4 reports
-
Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.Some support1 report
-
Pfizer is jointly marketing the drug Eliquis.Some support2 reports
-
Roivant Sciences licensed a drug from Pfizer for regulatory approval.Some support2 reports
-
Study results regarding a drug collaboration between Pfizer and Arvinas narrowed the focus to a specific subset of patients.Well supported4 reports
-
Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.Some support1 report
-
Altria, Pfizer, and Verizon stocks achieved high returns on September 8, 2026.Some support2 reports
-
Pfizer is developing the drug berobenatide for future growth, referencing its 2023 acquisition of Seagen.Some support3 reports
-
Scott Gottlieb served on the Pfizer board.Some support1 report
-
Lawsuit filed alleging Pfizer engaged in deceptive marketing regarding vaccine efficacy rates.Some support1 report
-
Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.Some support1 report
-
Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.Some support1 report
-
Pfizer's market outlook is being tied to the effects of Trump-era tariffs and onshoring trends.Some support1 report1 development inside
-
A pricing agreement between Pfizer and the Trump administration helped the company's stock rise.Some support1 report
-
Trump has threatened the use of tariffs to incentivize companies to move production back to the United States, impacting pharmaceutical imports.Well supported7 reports4 developments inside
-
Leadership announced a major agreement regarding the reduction of cancer medicine costs in Kenya, involving Pfizer.Some support3 reports
-
Starbucks CEO Brian Niccol guides company performance and outlook. Pfizer CEO Albert Bourla guides company performance and outlook. Both companies are evaluated as alternative investment targets.Some support2 reports
-
Pfizer is seeking approval for a Lyme vaccine, while the Theodore Roosevelt Conservation Partnership provides data on hunters.Some support2 reports1 development inside
-
Pfizer and Valneva are partnering on a Lyme vaccine and are currently seeking necessary approval from the FDA.Some support2 reports
-
FDA and Pfizer are seeking regulatory approval for their products.Some support1 report
One to three months ago
-
The FDA has approved the XFG variant formula for U.S. use, and Pfizer is now deploying the approved vaccine doses across the United States.Some support5 reports1 development inside
-
FDA guides preferred composition and Pfizer supplies vaccine to the U.S. market.Some support1 report
-
Pfizer's board of directors set the company's dividend policy on June 6, 2026, citing patent expirations and R&D challenges.Some support3 reports
-
Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.Some support1 report
-
Pfizer acquired Biohaven Pharmaceuticals, Seagen, and Arena Pharmaceuticals in transactions dating back to 2022.Some support2 reports1 development inside
-
Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.Some support1 report
-
Major pharmaceutical companies are part of the ten largest global pharma giants as the industry seeks to weaken drug price negotiation.Some support1 report
-
The House Judiciary Committee investigated Pfizer's vaccine timing, with Jim Jordan citing claims about delayed disclosure, while a Pfizer executive moved to GSK.Speculative1 report1 development inside
-
Details emerged regarding the early collaboration between Moderna, Pfizer, and the scientific community, including Katalin Karikó and University of Pennsylvania.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Pfizer this week
News at the entities that move Pfizer most-
Brooklyn Shared contextCoastal flooding and high tides are impacting infrastructure in Brooklyn and Far Rockaway.Moves Pfizer
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Pfizer
-
Novartis TransactionalNovartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Moves Pfizer
-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves Pfizer
-
Eli Lilly and Company OperationalExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Pfizer
-
Donald Trump StructuralThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Pfizer
Connections
The 40 strongest of 742, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Tina Graves Structural
Tina Graves was a former employee of Pfizer in Canada.
-
Brooklyn Shared context
Pfizer originated in Brooklyn, New York, in 1849.
-
Seagen Structural
Pfizer acquired Seagen in 2023 and integrated it as a subsidiary to bolster its oncology portfolio.
-
FDA Structural
The FDA formally regulates Pfizer's pharmaceutical products, determining market access through approvals, guidelines, and license management, including suspensions.
-
Albert Bourla Structural
Albert Bourla serves as the CEO and Chairman of Pfizer, directing its strategy, operations, and financial outlook.
-
David Denton Structural
David Denton served as the Chief Financial Officer of Pfizer during the observed period.
-
Cecile Structural
Cecile has been appointed the Interim Chief Financial Officer of Pfizer.
-
Arvinas (United States) Structural
Pfizer and Arvinas maintain a formal partnership to co-develop and submit vepdegestrant for breast cancer treatment.
Show all 40 connections
-
Novartis Transactional
Novartis acquired Pfizer's Minipress brand and trademarks in India.
-
Moderna Operational
Moderna and Pfizer are direct, high-stakes competitors in the biopharmaceutical market, primarily leveraging and competing within the mRNA technology platform.
-
Mylan Structural
Mylan was absorbed into the corporate structure stemming from Pfizer's Upjohn division, leading to the formation of Viatris.
-
AstraZeneca Operational
Pfizer and AstraZeneca are active competitors in major biopharma markets, including oncology and functional dyspepsia.
-
Eli Lilly and Company Operational
Pfizer and Eli Lilly are direct competitors vying for market share in high-growth pharmaceutical sectors, including GLP-1 weight loss and oncology.
-
Dave Denton Structural
Dave Denton held the formal executive role of Chief Financial Officer at Pfizer during this period.
-
Merck Operational
Pfizer and Merck are major pharmaceutical companies engaged in direct competition across key markets including oncology, candidemia, and glaucoma.
-
Dave Structural
Dave held executive and operational roles, including CFO, within Pfizer.
-
Donald Trump Structural
Pfizer's operations and pricing are structurally dependent on regulatory mandates and agreements established by the Trump administration.
-
Bristol-Myers Squibb Operational
Pfizer and Bristol-Myers Squibb are active market competitors while also engaged in formal product collaborations regarding the anticoagulant Eliquis.
-
Gensler Transactional
Gensler is contracted to lead the conversion project for Pfizer's building.
-
Johnson & Johnson Operational
Pfizer and Johnson & Johnson are major, publicly traded competitors in the global pharmaceutical market, facing shared market pressures like patent cliffs and pricing scrutiny.
-
Morgan Stanley Operational
Morgan Stanley actively tracks, rates, and invests in Pfizer stock, co-managing sales and increasing its stake in the company.
-
Arena Pharmaceuticals Structural
Pfizer acquired Arena Pharmaceuticals, establishing a parent-subsidiary relationship.
-
Medicare Structural
Pfizer's market access and revenue are structurally dependent on Medicare's drug negotiation and coverage policies.
-
Eurocontrol Transactional
Pfizer initiated proceedings to freeze Eurocontrol's operational funds to recover outstanding debt.
-
European Commission Structural
Pfizer's market operation in the EU is structurally dependent on the European Commission granting formal marketing authorizations for its products.
-
Wyeth Structural
Pfizer acquired Wyeth in 2009, and Wyeth operates as a dependent subsidiary within the larger corporate structure.
-
Michael Law Structural
Michael Law held a functional role on the media team of Pfizer.
-
Amgen Operational
Pfizer and Amgen are major pharmaceutical competitors actively developing and marketing treatments in specialized markets like weight loss, biosimilars, and thyroid care.
-
Control Data Corporation Structural
A is a critical customer of B, establishing a functional dependency on B's product supply and operational stability.
-
AbbVie Operational
AbbVie and Pfizer are direct, high-stakes competitors operating in the oncology and broader pharmaceutical markets.
-
King Pharmaceuticals Structural
King Pharmaceuticals operates as a dependent subsidiary of Pfizer.
-
RBC Capital Markets Operational
RBC Capital Markets actively advises and co-manages financial activities for Pfizer, including rating upgrades and asset sales.
-
Hoffmann-La Roche Operational
Pfizer and Hoffmann-La Roche are key competitors in specialized pharmaceutical markets, including Danon Disease and GLP-1 drug development, and share technology licensing strategies.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Pfizer maintain ongoing partnerships for drug development and supply.
-
Tô Lâm Operational
Tô Lâm and Pfizer engage in active cooperation regarding vaccine production and national health priorities.
-
European Medicines Agency Transactional
EMA formally validated Pfizer's vaccine application, initiating the assessment process.
-
Merck KGaA Operational
The companies actively compete in various therapeutic markets, collaborate on specific product approvals, and have engaged in corporate transactions.
-
Viking Therapeutics Operational
The companies are active competitors in the pharmaceutical market, with Pfizer's market shifts creating strategic interest in Viking Therapeutics.
-
Goldman Sachs International Transactional
Goldman Sachs coordinated and managed the sale of Pfizer's stake in a specific financial transaction.
-
Cecile Structural
Cecile holds a senior finance role, including SVP of Finance, within the organizational structure of Pfizer.
History
Events by the month they beganSeptember 2026
30 events- Dave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.
- Pfizer and other companies are facing administration policy guidance regarding higher drug prices abroad in exchange for revenue sharing with HHS.
- GSK built a joint venture with Pfizer and subsequently distributed a stake in that venture to shareholders.
- IMA Group operates a production site and manufacturing plant in Tonawanda, New York, providing specialized equipment to major customers like Pfizer and Moderna.
- Former Pfizer HQ in Manhattan is discussed alongside Los Angeles as examples of major urban centers facing development challenges and structural issues.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Pfizer, AT&T, and Verizon are companies that trade on the New York Stock Exchange.
- Kraft Heinz, Pfizer, and United Parcel Service are all facing financial challenges.
- Pfizer and Eli Lilly are being discussed as potential dividend investment targets.
- Pfizer and Seagen are growing their older-adult vaccine market share by expanding the Prevnar 20 vaccination program and rebuilding their commercial model around acquired products.
- Pfizer has refused to cooperate with local investigators regarding an incident in Karnataka.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- The FDA suspended Pfizer's C&F Depot license.
- The Administration negotiated confidential deals on drug prices using HHS officials, involving major pharmaceutical companies.
- Trump promised drug discounts for low-income Americans and discussed Pfizer deals at a Dallas convention.
- Pfizer CEO Ugur Sahin sold shares of the firm's stock.
- Vaxcyte is targeting the market dominated by Pfizer, and a key individual involved in the story previously worked at Pfizer.
- Pfizer and Boeing were tokenized for use in a crypto launchpad.
- DHS is piloting the 340B program, which affects products manufactured by Pfizer.
- Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.
- Medicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- Moderna's higher pricing is contrasted with GSK's and Pfizer's pricing in the context of a joint procurement agreement, which was deemed vital by Hadja Lahbib.
- Altria, Pfizer, and Verizon stocks achieved high returns on September 8, 2026.
- Pfizer is developing the drug berobenatide for future growth, referencing its 2023 acquisition of Seagen.
- Scott Gottlieb served on the Pfizer board.
- Lawsuit filed alleging Pfizer engaged in deceptive marketing regarding vaccine efficacy rates.
- Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.
- Pfizer is based in New York and Bristol-Myers Squibb is based in Princeton, New Jersey.
- A pricing agreement between Pfizer and the Trump administration helped the company's stock rise.
August 2026
14 events- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- The EMA has validated the Marketing Authorization Application (MAA) for a vaccine developed in collaboration between Valneva and Pfizer.
- Pfizer conducted initial clinical trials under government review.
- Rand Paul released Fauci's diary ahead of a hearing, while Israel provided Pfizer vaccine data to shape US booster policy.
- Leadership announced a major agreement regarding the reduction of cancer medicine costs in Kenya, involving Pfizer.
- Starbucks CEO Brian Niccol guides company performance and outlook. Pfizer CEO Albert Bourla guides company performance and outlook. Both companies are evaluated as alternative investment targets.
- Pfizer and Valneva are partnering on a Lyme vaccine and are currently seeking necessary approval from the FDA.
- FDA and Pfizer are seeking regulatory approval for their products.
- The FDA has approved the XFG variant formula for U.S. use, and Pfizer is now deploying the approved vaccine doses across the United States.
- FDA guides preferred composition and Pfizer supplies vaccine to the U.S. market.
- Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.
- Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
- Major pharmaceutical companies are part of the ten largest global pharma giants as the industry seeks to weaken drug price negotiation.
- Details emerged regarding the early collaboration between Moderna, Pfizer, and the scientific community, including Katalin Karikó and University of Pennsylvania.
July 2026
2 eventsShow 1 earlier month
June 2026
14 events- MarketBeat's screener has identified a list of dividend stocks.
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Trump's oil and gas pledges benefit US stocks, specifically impacting Pfizer.
- FDA granted approval for Pfizer's updated vaccine on September 2, 2025.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Pfizer is jointly marketing the drug Eliquis.
- Study results regarding a drug collaboration between Pfizer and Arvinas narrowed the focus to a specific subset of patients.
- Trump has threatened the use of tariffs to incentivize companies to move production back to the United States, impacting pharmaceutical imports.
- Pfizer is seeking approval for a Lyme vaccine, while the Theodore Roosevelt Conservation Partnership provides data on hunters.
- Pfizer's board of directors set the company's dividend policy on June 6, 2026, citing patent expirations and R&D challenges.
- Pfizer acquired Biohaven Pharmaceuticals, Seagen, and Arena Pharmaceuticals in transactions dating back to 2022.
- The House Judiciary Committee investigated Pfizer's vaccine timing, with Jim Jordan citing claims about delayed disclosure, while a Pfizer executive moved to GSK.